Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Tuberculosis (TB) remains the most important infectious disease in the world. Preventive
treatment plays an important role in successful control of TB. The investigators' previous
study showed a 3-month weekly rifapentine and isoniazid regimen had a high protective
efficacy but an unsatisfactory completion rate. Therefore, the investigators suppose that a
one-month (12-dose) regimen of rifapentine and isoniazid (1RPT/INH) to be equivalent to a
3-month weekly rifapentine and isoniazid regimen with similar efficacy and higher completion
rate. Relevant study is lacking in China where the TB burden is high with the incidence rate
of 70/100, 000.
Silicosis is a risk factor of Mycobacterium tuberculosis infection. This is an open-label,
non-randomized clinical trial to evaluate the efficacy and safety of the 1RPT/INH to prevent
tuberculosis (TB) compared with those who do not receive preventive treatment among silicotic
patients.